324P What affects the choice of first-line treatment for hormone-receptor-positive, HER2-negative advanced breast cancer? Data from the German research platform OPAL

Autor: Welt, A., Thill, M., Stickeler, E., Zahn, M-O., Nusch, A., Zaiss, M., Neef, U., Fruehauf, S., Buss-Steidle, R., Hagen, V., Chiabudini, M., Kruggel, L., Jänicke, M., Marschner, N.W., Wöckel, A., Harbeck, N., Decker, T.
Zdroj: In Annals of Oncology September 2020 31 Supplement 4:S373-S374
Databáze: ScienceDirect